RUNSTUDIO/DigitalVision via Getty Images
- Krystal Biotech is a promising biotech stock with strong revenue growth after the approval of its flagship product, VYJUVEK.
- VYJUVEK is a topical gene therapy for treating dystrophic epidermolysis bullosa and has the potential to generate substantial revenue.
- VYJUVEK’s weekly application ensures repeated revenue streams, with strong early adoption and high patient compliance.
- Its product pipeline in dermatology, respiratory, oncology, and ophthalmology could bring in additional revenue verticals.
- With a robust financial position and no debt, KRYS’s valuation appears reasonable, making it a “buy” at these levels.
Krystal Biotech, Inc. (NASDAQ:KRYS) is a promising commercial-stage biotech stock growing rapidly in its revenues after the recent approval of its flagship product, VYJUVEK. The company holds more than enough cash for the foreseeable future, and early commercialization efforts suggest that VYJUVEK will generate substantial revenue with strong gross margins. Moreover, the company seems to trade at a relatively reasonable valuation, assuming it maintains its margins going forward. Plus, its product pipeline could bring in additional revenue verticals as VYJUVEK’s revenue grows in the coming years. Hence, I think KRYS is a viable investment at these levels for investors aware of the inherent biotech risks.
READ FULL ARTICLE HERE!
